tirzepatide shortage resolved FDA says this weight loss drug is over, but patients worry about cost and availability FDA says shortage of GLP-1

Common side effects during the adjustment period (typically the first 24 weeks): Mild nausea usually less intense than when first starting a GLP-1 medication Changes in appetite (some patients notice less appetite suppression early on at the starting 0.25 mg dose) Mild stomach discomfort, bloating, or constipation Injection site reactions Side effects that are less likely during the switch (compared to first-time GLP-1 use), but still possible: Significant vomiting less common given prior GLP-1 exposure, but possible Hypoglycemia particularly relevant for type 2 diabetes patients on insulin or sulfonylureas

Generic oral semaglutide (Rybelsus equivalent) could be available as early as 2027 if Teva's application is approved

If you just have vaginal dryness, you may want to first try over-the-counter (OTC) moisturizers and lubricants: Dont use products that arent meant for your vagina (like face and body lotion)

Always follow your doctors advice and avoid using medications that are not specifically prescribed for your condition

Use the appetite suppression window to establish eating patterns, exercise habits, and mindset shifts that can persist even when pharmacological support ends

Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties